US FDA to take renewed action against opioid epidemic

27 February 2019

US Food and Drug Administration Commissioner Scott Gottlieb has released a statement outlining new actions his agency plans to take to tackle the opioid crisis in the USA.

The FDA will take steps to reduce misuse and abuse of opioids, support addiction recovery, support R&D into non-addictive pain treatments and strengthen enforcement against illicit opioids.

Against a background of research which increasingly suggests opioids are not an effective option for pain management in the long term, the agency will start to require drugmakers to study long term efficacy of new opioid products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK